HO-3867 is a curcumin analog designed to overcome the limitations of curcumin, such as poor solubility and low bioavailability, while enhancing its anticancer properties. It has shown strong potential in cancer research due to its ability to selectively target cancer cells and induce apoptosis. The compound acts as a STAT3 inhibitor, blocking a key signaling pathway involved in tumor growth, survival, and resistance to therapy. This makes HO-3867 a promising candidate for treating cancers that overexpress STAT3, such as ovarian, breast, lung, and prostate cancers. In preclinical studies, HO-3867 has demonstrated the ability to suppress tumor growth and reduce metastasis. It also enhances the effectiveness of conventional chemotherapy agents, suggesting its potential use in combination therapies. Additionally, HO-3867 exhibits antioxidant properties in normal cells while promoting oxidative stress in cancer cells, contributing to its selective toxicity toward malignant cells. Due to its stability and improved pharmacokinetic profile, HO-3867 is being explored for development as a targeted therapeutic agent, particularly in resistant or aggressive cancers. Research is ongoing to evaluate its efficacy and safety for future clinical applications.